📑Ajuste Direto n.o 141G003093.
Procurement process summary
This process is to purchase Ajuste Direto n.o 141G003093.
This contract was awarded by 🇵🇹 Centro Hospitalar Lisboa Norte, EPE for an amount of EUR 248,500 to 1 supplier. It was published on 2014-09-24 through selective
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
Buying entity🇵🇹 Centro Hospitalar Lisboa Norte, EPE Buying unitnot reported Publication date2014-09-24 Contest statusnot reported DescriptionAquisicao de Infliximab sol. inj. 100 mg.Awards
This award was granted to Merck Sharp & Dohme, Lda by Centro Hospitalar Lisboa Norte, EPE for an amount of EUR 248,500. The procurement process was conducted through selective for the category of goods. The award was granted on 2014-08-26. This is award number 1.
| Supplier | Amount | Award date | Award number |
|---|---|---|---|
| 🇪🇺 Merck Sharp & Dohme, Lda | EUR 248,500 | 2014-08-26 | 1 |
Market context and opportunities
The execution of this contract allows the entity Centro Hospitalar Lisboa Norte, EPE to fulfill its public service objectives efficiently.
The selective purchase modality ensures that the process is transparent and compliant with regulations.
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
This transparency in public procurement promotes fair competition, prevents corruption, and ensures that public resources are used efficiently for the benefit of citizens.
Additional data
Contract NumberPT_ocds-70d2nz-327b8fdc-9ebe-47c8-8928-633971ff0cca-award-1Publication date2014-09-24Contract datenot reportedAward date2014-08-26CategoriesgoodsPurchase modalityselectiveMethod detailspt_accelerated_negotiatedStatusnot reportedData sources
Sociedad.info publishes data from official sources, in compliance with public information access laws. Public access to this data is a civic right that helps hold government accountable. This data, including names and identifiers, is already public in the official source. Read our privacy policy.
